secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001193125-21-323744
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q3 2021 net loss $19.6M; cash $503.8M funds into H2 2024
---------------------------------------------------------------------------

- Net loss of $19.6M ($0.28/share) vs $26.8M ($0.76) in Q3 2020; loss narrowed on revenue change.
- Cash, equivalents and marketable securities $503.8M; management expects to fund operations into H2 2024.
- Collaboration revenue was $6.8M vs negative $11.3M a year ago, due to Gilead amendment charge in Q3 2020.
- TNG908 IND on track for Q4 2021; Phase 1/2 trial initiation expected in H1 2022.
- Closed business combination with BCTG Acquisition Corp. and PIPE, yielding gross proceeds of $342M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312521323744/0001193125-21-323744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312521323744/d256728d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-323744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer